These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26498005)

  • 21. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.
    Ge C; Li R; Song H; Geng T; Yang J; Tan Q; Song L; Wang Y; Xue Y; Li Z; Dong S; Zhang Z; Zhang N; Guo J; Hua L; Chen S; Song X
    BMC Cancer; 2017 Dec; 17(1):884. PubMed ID: 29268708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
    Huang A; Zhang B; Wang B; Zhang F; Fan KX; Guo YJ
    Cancer Immunol Immunother; 2013 Sep; 62(9):1439-51. PubMed ID: 23760662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study.
    Bernhardt SL; Gjertsen MK; Trachsel S; Møller M; Eriksen JA; Meo M; Buanes T; Gaudernack G
    Br J Cancer; 2006 Dec; 95(11):1474-82. PubMed ID: 17060934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients.
    Choi HS; Ha SY; Kim HM; Ahn SM; Kang MS; Kim KM; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kang ES
    Oncotarget; 2016 Feb; 7(7):7940-51. PubMed ID: 26799288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer vaccination with telomerase peptide GV1001.
    Kyte JA
    Expert Opin Investig Drugs; 2009 May; 18(5):687-94. PubMed ID: 19388882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
    Ellingsen EB; Aamdal E; Guren T; Lilleby W; Brunsvig PF; Mangsbo SM; Aamdal S; Hovig E; Mensali N; Gaudernack G; Inderberg EM
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35613827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
    Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
    Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy.
    Pal S; Nandi M; Dey D; Chakraborty BC; Shil A; Ghosh S; Banerjee S; Santra A; Ahammed SKM; Chowdhury A; Datta S
    Aliment Pharmacol Ther; 2019 May; 49(10):1346-1359. PubMed ID: 30982998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.
    Tarhini AA; Butterfield LH; Shuai Y; Gooding WE; Kalinski P; Kirkwood JM
    J Immunother; 2012; 35(9):702-10. PubMed ID: 23090079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
    Vetsika EK; Konsolakis G; Aggouraki D; Kotsakis A; Papadimitraki E; Christou S; Menez-Jamet J; Kosmatopoulos K; Georgoulias V; Mavroudis D
    Cancer Immunol Immunother; 2012 Feb; 61(2):157-168. PubMed ID: 21858533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.
    Kyte JA; Trachsel S; Risberg B; thor Straten P; Lislerud K; Gaudernack G
    Cancer Immunol Immunother; 2009 Oct; 58(10):1609-26. PubMed ID: 19221745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.
    Gridelli C; Ciuleanu T; Domine M; Szczesna A; Bover I; Cobo M; Kentepozidis N; Zarogoulidis K; Kalofonos C; Kazarnowisz A; Korozan M; de Las Penas R; Majem M; Chella A; Griesinger F; Bournakis E; Sadjadian P; Kotsakis A; Chinet T; Syrigos KN; Correale P; Gallou C; Jamet JM; Vetsika EK; Kosmatopoulos K; Georgoulias V;
    Br J Cancer; 2020 May; 122(10):1461-1466. PubMed ID: 32210365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation.
    Ke X; Zhang S; Xu J; Liu G; Zhang L; Xie E; Gao L; Li D; Sun R; Wang F; Pan S
    Cancer Immunol Immunother; 2016 May; 65(5):587-99. PubMed ID: 27000869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
    Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
    J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity.
    Garg A; Spector SA
    J Infect Dis; 2014 Feb; 209(3):441-51. PubMed ID: 23999600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer.
    Skachkova OV; Khranovska NM; Gorbach OI; Svergun NM; Sydor RI; Nikulina VV
    Exp Oncol; 2013 Jun; 35(2):109-13. PubMed ID: 23828386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
    Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
    Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of CD4
    Wang J; Yang J
    Biomed Rep; 2016 Aug; 5(2):208-212. PubMed ID: 27446543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.